The method to develop AAV2-SIRT3 microbubble drug conjugates (MDCs) for MR-g-FUS mediated delivery described in this study may be used to develop MDCs for a variety of viral vectors, for example, AAV2, AAV9, lentiviral, HSV, which could potentially be used to treat a variety of neurological disorders, including neurodegenerative diseases. The gene discussed is SIRT3; the disease is neurodegenerative disease.